Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Efficacy of Sarilumab in Combination with Csdmards in Patients with Rheumatoid Arthritis and Inadequate Response to TNF Inhibitors By Baseline Levels of Disease Activity

被引：0
|
作者：
Fleischmann, Roy [1 ]
van Hoogstraten, Hubert [2 ]
Jayawardena, Shyamalie [2 ]
Mangan, Erin K. [3 ]
Ching, Daniel [4 ]
Burmester, Gerd R. [5 ,6 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA
[2] Sanofi Genzyme, Bridgewater, NJ USA
[3] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[4] Timaru Med Specialists Ltd, Timaru, New Zealand
[5] Free Univ, Charite Univ Med Berlin, Rheumatol & Clin Immunol, Berlin, Germany
[6] Humboldt Univ, Berlin, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2471
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
    Fleischmann, Roy
    van Adelsberg, Janet
    Lin, Yong
    Castelar-Pinheiro, Geraldo da Rocha
    Brzezicki, Jan
    Hrycaj, Pawel
    Graham, Neil M. H.
    van Hoogstraten, Hubert
    Bauer, Deborah
    Burmester, Gerd R.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69 (02) : 277 - 290
  • [2] Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
    Fleischmann, Roy
    St. John, Greg
    Kimura, Toshio
    Iglesias-Rodriguez, Melitza
    Rosner, Itzhak
    Burmester, Gerd R.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [3] SUSTAINED RESPONSE IN A PHASE 3 STUDY OF SARILUMAB PLUS NONBIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH ACTIVE, MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR INHIBITORS
    Fleischmann, R.
    St John, G.
    Kimura, T.
    Iglesias-Rodriguez, M.
    van Hoogstraten, H.
    Rosner, I
    Burmester, G. R.
    [J]. INTERNAL MEDICINE JOURNAL, 2018, 48 : 21 - 22
  • [4] EFFICACY OF SARILUMAB IN COMBINATION WITH CSDMARDS IN PATIENTS WITH RHEUMATOID ARTHRITISAND INADEQUATE RESPONSE TO TNF INHIBITORS BY BASELINE LEVELS OF DISEASEACTIVITY
    Fleischmann, Roy
    van Hoogstraten, Hubert
    Jayawardena, Shyamalie
    Mangan, Erin K.
    Chings, Daniel
    Burmester, Gerd R.
    [J]. RHEUMATOLOGY, 2018, 57
  • [5] Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
    Ernest Choy
    Nick Freemantle
    Clare Proudfoot
    Chieh-I Chen
    Laurence Pollissard
    Andreas Kuznik
    Hubert van Hoogstraten
    Erin Mangan
    Paulo Carita
    Thi-Minh-Thao Huynh
    [J]. Advances in Therapy, 2019, 36 : 817 - 827
  • [6] Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
    Choy, Ernest
    Freemantle, Nick
    Proudfoot, Clare
    Chen, Chieh-I
    Pollissard, Laurence
    Kuznik, Andreas
    van Hoogstraten, Hubert
    Mangan, Erin
    Carita, Paulo
    Thi-Minh-Thao Huynh
    [J]. ADVANCES IN THERAPY, 2019, 36 (04) : 817 - 827
  • [7] SUSTAINED RESPONSE IN A PHASE III STUDY OF SARILUMAB PLUS NONBIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH ACTIVE, MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR INHIBITORS
    Fleischmann, Roy
    St John, Greg
    Kimura, Toshio
    Iglesias-Rodriguez, Melitza
    Rosner, Itzhak
    Burmester, Gerd R.
    [J]. RHEUMATOLOGY, 2018, 57
  • [8] Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
    Alvin F. Wells
    Janie Parrino
    Erin K. Mangan
    Anne Paccaly
    Yong Lin
    Christine Xu
    Chunpeng Fan
    Neil M. H. Graham
    Hubert van Hoogstraten
    Albert Torri
    [J]. Rheumatology and Therapy, 2019, 6 : 339 - 352
  • [9] Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
    Wells, Alvin F.
    Parrino, Janie
    Mangan, Erin K.
    Paccaly, Anne
    Lin, Yong
    Xu, Christine
    Fan, Chunpeng
    Graham, Neil M. H.
    van Hoogstraten, Hubert
    Torri, Albert
    [J]. RHEUMATOLOGY AND THERAPY, 2019, 6 (03) : 339 - 352
  • [10] Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis A Randomized Trial
    Kremer, Joel
    Li, Zhan-Guo
    Hall, Stephen
    Fleischmann, Roy
    Genovese, Mark
    Martin-Mola, Emilio
    Isaacs, John D.
    Gruben, David
    Wallenstein, Gene
    Krishnaswami, Sriram
    Zwillich, Samuel H.
    Koncz, Tamas
    Riese, Richard
    Bradley, John
    [J]. ANNALS OF INTERNAL MEDICINE, 2013, 159 (04) : 253 - +
12345